COVID-19 Resources for North Carolina Life Science Companies and Researchers
Given the role North Carolina's life science community are playing in response to the COVID-19 virus, and the effect the outbreak is having on business operations, this page compiles resources and news relevant to local life science companies and researchers.
Last update: May 27, 2020
ADVANSE Virtual Pitch Rounds: COVID-19 (Southeast Life Sciences)
Deadline: May 29, 2020
Calling All Southeast Life Science Innovators: If your early-stage or seed-stage company is innovating in the life sciences space impactful to COVID-19 solutions, we want to see your pitch! We encourage southeast-based early stage medtech and life science companies in any aspect of healthcare - diagnostics, treatments, vaccines, telehealth technologies, devices and even hygienics and PPE to apply. The inaugural virtual event will follow the same format as our in-person PitchRounds events. Selected companies will make 10-minute presentations followed by Q&A from our investor panel.
See this guide from Octopus Ventures for tips on remote pitching.
Rapid Acceleration of Diagnostics (RADx) initiative (NIH)
The National Institutes of Health announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) initiative will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing.
As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19.
2019 Novel Coronavirus Medical Countermeasure Partnership Opportunities (BARDA)
BARDA is working with its partners to identify promising medical countermeasures and technologies to combat the 2019 novel coronavirus. There are three ways your company or organization can partner with BARDA to fight the ongoing novel coronavirus outbreak.
BARDA has also created the CoronaWatch Portal seeking information and meeting requests from stakeholders on available medical countermeasures in development. See BARDA's COVID-19 Medical Countermeasure portfolio here.
Funding Opportunities Specific to COVID-19 (NIH)
The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, the NIH wants to assure its recipient community that NIH will be doing its part to help you continue your research.See NIH guidance for applicants and recipients, as well as these funding opportunities.
Letter on the COVID-19 (NSF)
NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, they NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events.
See other NSF Guidance here.
SBIR/STTR Phase I Proposals Addressing COVID-19 (NSF)
Deadline: Current submission window ends June 4, 2020
The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.
Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) (NIH and NIAID)
Deadline: Letter of Intent due May 30, 2020; application due June 29, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (DHHS)
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
- Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
- Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01) (DHHS)
Deadline: Letter of intent - June 1; Application - June 15
This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic.
Congressionally Directed Medical Research Programs (CDMRP)
The following award mechanisms are available for emerging viral diseases and respiratory health.The proposed research must be relevant to active duty service members, veterans, military beneficiaries, and/or the American public.
- Clinical Trial Award (Deadline: Letter of Intent due June 8, 2020; application due June 22, 2020)
- Investigator-initiated Research Award (Deadline: Letter of Intent due May 28, 2020; application due June 12, 2020)
- Technology/Therapeutic Development Award (Deadline: Letter of Intent due May 28, 2020; application due June 12, 2020)
Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (NLM)
Deadline: June 17, 2020
In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NLM is encouraging the submission of R21 applications to address the following research areas of interest:
- Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets
- Public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2
Rapid Response to Novel Coronavirus Impacts Across Food and Agricultural Systems (USDA Agriculture and Food Research Initiative)
Deadline: June 4, 2020
The AFRI Foundational and Applied Science Program supports grants in six AFRI priority areas to advance knowledge in both fundamental and applied sciences important to agriculture. The six priority areas are: Plant Health and Production and Plant Products; Animal Health and Production and Animal Products; Food Safety, Nutrition, and Health; Bioenergy, Natural Resources, and Environment; Agriculture Systems and Technology; and Agriculture Economics and Rural Communities.
Manufacturing USA National Emergency Assistance Program (National Institute of Standards and Technology (NIST))
NIST invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.
Patient-Centered Outcomes Research Institute Funding Opportunities (PCORI)
The Patient-Centered Outcomes Research Institute was created to improve the evidence about what works in health care to better inform real, specific choices faced by patients, clinicians, healthcare administrators and others in the healthcare communities. All open funding opportunities, including COVID-19 related opportunities, are listed here.
Research Grant for Pandemic Preparedness (Merck)
Research grants for technological solutions towards pandemic outbreak preparedness or solutions that could help fighting emerging viral infections.
Emergency Response for the Health Care System Innovation Challenge (Robert Wood Johnson Foundation)
Deadline: June 12
Can you create a digital tool supporting the health care system (including but not limited to providers, government, and public health and community organizations) during a large-scale health crisis (pandemic, natural disaster, or other public health emergency)? This innovation challenge is for technologies that support the health care system such as providers, government, and public health and community organizations.
Emergency Response for the General Public Innovation Challenge (Robert Wood Johnson Foundation)
Deadline: June 12
Can you build a health technology tool to support the needs of individuals affected by a large-scale health crisis (pandemic, natural disaster, or other public health emergency)? A large-scale health crisis such as the current COVID-19 pandemic, or natural disasters, can disrupt the lives of everyone in an affected community. The public faces numerous challenges during these events such as rapidly spreading misinformation, shortages of supplies like medications, and lack of access to resources and health care. Digital health tools have the capacity to support individuals during these critical periods.
Health Security and Pandemics Challenge (MIT Solve)
Deadline: June 18, 2020
MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.
Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19 (Coalition for Epidemic Preparedness Innovations (CEPI))
Deadline: Rolling, open until at least June 30
The objective of this Call for Proposals is to support the rapid development of vaccines with a goal of achieving licensure/emergency authorization in 12-18 months or less and to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021. This call is being issued in conjunction with the establishment of the Access to COVID-19 Tools (ACT) Accelerator (https://www.who.int/who-documents-detail/access-to-covid-19-tools-(act)-accelerator), a public-private partnership committed to speeding the development of and global access to diagnostics, therapeutics, and vaccines.
AWS Diagnostic Development Initiative (DDI) (Amazon Web Service)
Deadline: June 30, 2020
The AWS Diagnostic Development Initiative (DDI) provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks. Although vaccine and treatment development research is generally funded by private foundations and government agencies, fast and reliable diagnostic techniques are slow to be developed. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies.
Fast Funding for COVID-19 Science (Fast Grants/Emergent Ventures)
Deadline: Currently paused
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you'll receive payment as quickly as your university can receive it.
Note about tests developed in North Carolina:
Numerous companies and researchers in North Carolina are working on tests and potential vaccines for COVID-19, but NCBiotech doesn’t directly do any scientific research and we do not sell any products. Healthcare providers can learn more about tests currently on the market and order at the following websites:
- BioMedomics' COVID-19 IgM/IgG Rapid Test
Contact a representative at 1-800-P-SCHEIN (800-772-4346) or email@example.com.
- Cellex qSARS-COV-2 IgG/IgM Rapid Test
- LabCorp's Pixel at-home test kit
If you are trying to reach one of the other companies mentioned on this page, please contact them directly. If you need help, you might be able to find the company you want in our Company Directory.
Resources and Initiatives
- BIO COVID-19 Therapeutic Development Tracker
BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the Covid-19 pipeline, updated every Monday.
- Milken Institute COVID-19 Treatment and Vaccine Pipeline
The Milken Institute is tracking the development of potential treatments and vaccines in development for COVID-19.
- BIO COVID-19 Therapeutic Development Tracker
Federal Initiatives and Response
- Coronavirus (COVID-19) Drug Information from the FDA
The Center for Drug Evaluation and Research (CDER) is engaged in numerous activities to protect and promote public health during the COVID-19 pandemic, ranging from the acceleration of development for treatments for COVID-19, maintaining and securing drug supply chains, providing guidance to manufacturers, advising developers on how to handle clinical trial issues, and keeping the public informed. Descriptions of efforts led by CDER are linked.
- Coronavirus Treatment Acceleration Program (CTAP)
The FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership
The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic.
- Operation Warp Speed
The Trump administration is prioritizing 14 potential vaccine candidates to undergo further testing, with the goal of having as many as 300 million doses by early 2021.
- Coronavirus (COVID-19) Drug Information from the FDA
The Road to a Vaccine
Airs at 12:00 P.M. on jnj.com, Facebook, LinkedIn and Twitter.
This new eight-episode educational video series sponsored by Johnson & Johnson will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine. Each week, host Lisa Ling will talk to leading scientists and researchers, healthcare workers on the front lines and public health experts around the world working collaboratively to bring an end to the deadly pandemic.
COVID-19 Research Datasets
Open-Access Data and Computational Resources to Address COVID-19 (NIH)
COVID-19 open-access data and computational resources are being provided by federal agencies, including NIH, public consortia, and private entities. These resources are freely available to researchers, and this page will be updated as more information becomes available.
- CAS COVID-19 Antiviral Candidate Compounds Dataset
CAS has built an open source dataset assembled from CAS REGISTRY® including known anti-viral drugs and related chemical compounds that are structurally similar to known antivirals. The dataset license terms support use for applications including research, data mining, machine learning, and analytics at no charge.
- CAS COVID-19 Protein Target Thesaurus
The CAS COVID-19 Protein Target Thesaurus is a collection of the high-profile targets linked to SARS-CoV-2. This information will be valuable to scientists and IP professionals who are seeking to comprehensively search for information about COVID-19 targets.
- COVID-19 Research Database
The COVID-19 research database is a collection of data sets made freely available to public health and policy researchers to extract insights for combatting the COVID-19 pandemic. The dataset is a pro-bono, cross-industry collaboration. Until now, researchers and policy-makers seeking to answer questions about the pandemic could only do research on fragmented data sets (such as the data set from a particular hospital), or to conduct long, prospective clinical trials, which makes it difficult to rapidly answer questions about the epidemiology and treatment of the disease. The COVID-19 research database is a consortium of institutions pooling their de-identified and limited pandemic-related data to allow researchers to more rapidly conduct studies at a large scale.
- COVID-19 Open Research Dataset Challenge (CORD-19) (Kaggle)
The CORD-19 dataset represents the most extensive machine-readable coronavirus literature collection available for data mining to date. This allows the worldwide AI research community the opportunity to apply text and data mining approaches to find answers to questions within, and connect insights across, this content in support of the ongoing COVID-19 response efforts worldwide.
COVID-19 and Coronavirus Plasmids (Addgene)
Addgene is a non-profit plasmid repository that facilitates the exchange of genetic material between laboratories. On this page, Addgene is compiling plasmids containing SARS-CoV-2 sequences and other resources available to industry, academics and nonprofits.
Disqover COVID-19 (Ontoforce)
Ontoforce is making available a free COVID-19 dashboard that brings together patents, publications and clinical studies. Linked to these resources are related diseases and health conditions; genes and phenotypes; drugs, chemicals and active substances. Log in is required.
CARES Act (Federal Coronavirus Aid Package)
The Coronavirus Aid, Relief, and Economic Security (CARES) Act established several new temporary programs administered through the SBA to address the COVID-19 outbreak.
- SBA Payroll Protection Program
The SBA resumed accepting Paycheck Protection Program applications from participating lenders on Monday, April 27, 2020.
The Payment Protection Program authorizes up to $349 billion in forgivable loans, up to $10M per company, to small businesses to pay their employees during the COVID-19 crisis. The loan will be fully forgiven if the funds are used for payroll costs, interest on mortgages, rent, and utilities. Loan payments will also be deferred for six months. Find eligible lenders.
The loan forgiveness application is available here.
- Economic Injury Disaster Loan
Note: SBA will begin accepting new Economic Injury Disaster Loan (EIDL) and EIDL Advance applications on a limited basis only to provide relief to U.S. agricultural businesses. Applicants who have already submitted their applications will continue to be processed on a first-come, first-served basis.
Small business owners of less than 500 employees in all U.S. states and territories are currently eligible to apply for a low-interest Economic Injury Disaster loan of up to $10,000 due to Coronavirus (COVID-19).
- SBA Express Disaster Bridge Loan
If a small business has an urgent need for cash while waiting for decision and disbursement on Economic Injury Disaster Loan, they may qualify for an SBA Express Disaster Bridge Loan of up to $25,000.
- SBA Debt Relief
The SBA will automatically pay the principal, interest, and fees of current 7(a), 504, and microloans for a period of six months.The SBA will also automatically pay the principal, interest, and fees of new 7(a), 504, and microloans issued prior to September 27, 2020
- Coronavirus (COVID-19): Small Business Guidance & Loan Resources (SBA)
- See the Small Business Owner's guide to the CARES Act here.
- The SBTDC's SBA Loan overview is available here, or see their full COVID-19 resource guide here.
- SBA Payroll Protection Program
Main Street Lending Program (Federal Reserve)
The Federal Reserve is establishing a Main Street Lending Program to support lending to small and medium-sized businesses (fewer than 10,000 employees) that were in good financial standing before the onset of the COVID-19 pandemic. The program will operate through two facilities: the Main Street New Loan Facility (MSNLF) for newly originated loans to eligible businesses, and the Main Street Expanded Loan Facility (MSELF) for companies to upsize existing loans. Unlike the SBA's Paycheck Protection Program under the CARES Act, loans will not be eligible for full or partial forgiveness.
Guidance from the U.S. Chamber of Commerce is available here.
North Carolina Business Relief Resources (EDPNC)
Low-interest lending options, layoff aversion resources, and other small business relief resources.
NC Covid-19 Rapid Recovery Loan Program (Golden LEAF Foundation)
In response to the unique economic challenges of COVID-19, a consortium of public, private, and nonprofit partners have come together and launched an innovative recovery-lending program to help support entrepreneurs like you and stabilize North Carolina’s small business sector.
Wake Forward (Wake County)
Recognizing that small businesses are the backbone of our community, Wake County has launched Wake Forward, a small business relief program that aims to provide loans to small business owners struggling financially due to COVID-19. The goal is to help them in the short-term, so they can get back on their feet in the long-term. Eligible companies must be located in Wake County and have between 1-100 full-time employees.
COVID-19 Mecklenburg Small Business Emergency Stabilization Loan
Note: As of April 16, funding is no longer available; however, applications are still being accepted on a first-come, first-serve basis in the event that new funding becomes available for loans.
In recognition of the short and long-term impact that COVID-19 is having on the county’s entrepreneurial ecosystem, Mecklenburg County government has established a loan fund in partnership with the Carolina Small Business Development Fund. The fund provides affordable financing in amounts ranging from $5,000 to $35,000 for qualifying small businesses that have been adversely impacted by the pandemic. Funds may be used to cover the day-to-day operating expenses of the business.
Coronavirus Tax Relief
The filing deadline for federal income taxes been extended from April 15 to July 15, 2020.
The CARES Act allows employers to defer the deposit and payment of the employer's share of Social Security taxes and self-employed individuals to defer payment of certain self-employment taxes.Companies who have loans forgiven under the CARES Act’s Paycheck Protection Program are not eligible to defer these payroll taxes, but companies can get the payroll tax deferral until the loan is forgiven. Read more.
The N.C. Department of Revenue (NCDOR) has also extended the April 15 tax filing deadline to July 15 for individual, corporate, and franchise taxes to mirror the announced deadline change from the Internal Revenue Service. Read more.
JPMorgan Chase Philanthropic Investment
JPMorgan Chase announced a $50 million global philanthropic commitment to address the immediate public health and long-term economic challenges from the COVID-19 global pandemic. $8M from this commitment is for small business assistance, specifically to aid Black, Hispanic and Asian Pacific Islander-owned businesses.
COVID-19 Federal Rural Resource Guide (USDA)
USDA and its Federal partners have programs that can be used to provide immediate and long-term assistance to rural communities affected by the COVID-19 outbreak. These programs can support recovery efforts for rural residents, businesses and communities through technical, training and management assistance; financial assistance; and state and local assistance.
The US Chamber is offering ongoing virtual town halls and workshops to understand business relief resources and strategies for continuing business operations.
The BIO Coronavirus Hub is the primary life scicence-focused resource to connect companies that have relevant supplies, capacities, and resources to share, with those companies, researchers, or healthcare providers that need them. The new hub will enable users to post requests for urgently needed items, as well as to post the availability of supplies and capacity. Connections for medical supplies will be facilitated in partnership with Healthcare Ready to ensure an organized and optimized allocation of items in need, and thus will not be publicly available or searchable.
COVID-19 Survivors in North Carolina needed for convalescent plasma donation
For individuals who have recovered from COVID-19, donating plasma is a great way to make a difference during this exceptional time. For information about plasma donation opportunities through Grifols in North Carolina, please visit www.grifolsplasma.com/en/endcv19 or call 1-866-END-CV19.
Grifols is a global healthcare company with a major presence in our state. The company is playing a leadership role in the response to COVID-19 by developing a plasma-based antibody treatment for the disease. Through partnerships with the Biomedical Advanced Research and Development Authority, Food and Drug Administration, and National Institutes of Health, Grifols is collecting convalescent plasma from eligible COVID-19 survivors across the country. Grifols’ 13 plasma collection centers in North Carolina are participating in this important effort. Convalescent plasma from donors will be manufactured into a hyper-immune therapy specific to COVID-19 at Grifols’ manufacturing facility in Clayton, NC.
Also see the National COVID-19 Convalescent Plasma Project from Michigan State University for more information about donating and using convalescent plasma.
NC DHHS Calls for Health Care Volunteers
The North Carolina Department of Health and Human Services (NC DHHS) is calling for health care volunteers to assist with the COVID-19 response. They are seeking volunteers in the following areas: Clinical (physicians, advanced care providers, nurses, EMS); Clinical Support (pharmacy, imaging and respiratory care); Non-clinical Support (facility maintenance, safety, administrative). The full letter is available here.
Critical Supply Production Database
IES/NCMEP is building a database of companies with certain capabilities during this critical time. There are over 20 critical supplies needed to respond to COVID-19. If your company currently does or can quickly begin production, please fill out the information below. NCMEP will share this information with federal and state stakeholders such as the US Department of Commerce and NCDPS Emergency Management agency to help meet these needs. Furthermore, your secured information provides us with crucial analytical data to dynamically generate topics, related companies, and resources.
COVID-19 National Scientist Volunteer Form
This is a database of scientists who are able to volunteer time, expertise, equipment, and consumables to help government entities, non-profits, universities and local organizations respond to the COVID-19 crisis.
MBAs Fight COVID-19
This initiative from Harvard Business School connects MBA students across the country who can offer their skills to organizations in the public, private and social sectors.
Your Weekly Briefing: RTI COVID-19 U.S. Survey Results Webinar Series
Every Wednesday through May, 12:00 p.m.
Public knowledge and perception of the novel coronavirus (COVID-19) can help shape the federal, state, and local governments’ response to the pandemic and indicate whether those strategies are effective. In this four-part webinar series, we will share the outcomes from the RTI-funded survey and provide a detailed analysis of the implications from that data.
Navigating the Great Pause
Host: Innovate Carolina
Every Thursday through May at 12:00
This series is co-hosted by the UNC Entrepreneurship Center and NC Growth to help our stakeholders and community make it through the COVID-19 situation and come out stronger on the other side.
Clinical Trials in the Era of COVID-19 Weekly Webinar Series
Host: WCG Clinical
The continuing spread of COVID-19 has the industry’s undivided attention, as clinical trial professionals seek the latest perspective on best practices during this unprecedented time. Clinical researchers with ongoing or upcoming clinical trials are working to understand, and ameliorate the impact of this pandemic on studies to keep them on track. Join thousands of peers in these weekly online panels, designed to support healthcare researchers via the industry’s leading voices and perspectives. The panelists share expertise in real-time to inform our collective efforts to discover effective therapies, and minimize the disruption to ongoing and upcoming clinical trials.
Startups Supporting Startups: Advice on Success and Persistence During Tough Economic Times
Host: Kickstart Venture Service
May 28, 1:00 p.m.
Panelists will discuss ways startups can adapt and remain productive during the current economic climate. In attendance:
- Ricky Spero, Redbud Labs
- David Spratte, Carpe
- Marty Waters, Wilson Sonsini
- Ben Scrugge, Hatteras Venture Partners
“Alternative Funding Models” - Thriving or Surviving Through Investment Disruption
Host: SouthEast Life Sciences
May 28, 2:00 p.m.
COVID-19 has changed our world. For growing life science innovation companies, the same old status quo with investors may not work in the short-term. On May 28 at 2:00, Southeast Life Sciences virtually sits down with leaders across the spectrum who work with dozens of companies like yours to help us navigate and learn new survival skills using alternative funding sources and operational hacks. Now is the time to learn and investigate resources out there that might provide a boost, or even a lifeline, in these challenging times.
COVID-19 Bending the Curve
Host: PhRMA and McClatchy
May 28 - June 11, 12:30 p.m.
A livestreamed three-part series bringing together top medical professionals, industry experts, patient advocates and policymakers to discuss the latest advancements for combating the novel coronavirus
Innovation & Treatment | Thursday, May 28
The Path to a Vaccine | Thursday, June 4
Impact on Health Care Policy | Thursday, June 11
Leading During Difficult Times
Host: SouthEast Life Sciences
June 12, 12:00 p.m.
As leaders, we are all actively involved in dealing with the implications of COVID-19. We invite you to join a one-hour webinar entitled, Your Rx for Leading During Difficult Times. This one-hour webinar allows us to hear from Dr. Wendy Heckelman, a change leadership expert on how we can be effective when dealing with crisis and change.
Many journals and publishers are committing to making coronavirus and COVID-19 research articles free to access.
LitCovid from the National Library of Medicine
LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus. It is the most comprehensive resource on the subject, providing a central access to 842 (and growing) peer-review articles.
Ontoforce is making available a free COVID-19 dashboard that brings together patents, publications and clinical studies. Linked to these resources are related diseases and health conditions; genes and phenotypes; drugs, chemicals and active substances. Log in is required.
Safely Reopening Under OSHA (Smith Anderson)
May 28, 1:00 p.m.
The webinar will cover OSHA requirements applicable to workplaces as employees return, including certain guidance offered by the Centers for Disease Control and Prevention. In addition, employers will be offered insights and practical tips regarding best practices, dealing with employee complaints, reporting and record keeping and multi-employer workplaces. Registrants will be able to submit questions upon registering, and there will be a live Q&A available.
The recent and ongoing COVID-19 Pandemic is requiring new paradigms and a fundamental shift in how we think about research design and space use at all levels of interaction. With the goal of lessening density and creating safer environments, many perspectives will be needed to plan for safe and effective solutions.
These recommendations for #OpenSafely were published in on May 20, 2020 by a group of bipartisan health policy experts and leaders from broad and diverse backgrounds including Andy Slavitt; Mark McClellan, MD, PhD; and others.
Reopening Playbook (The Chamber for a Greater Chapel Hill-Carrboro)
A guide to provide organizations with the best known guidance to ensure consumer confidence and promote community health in the age of COVID-19.
These modules provide evidence-based COVID-19 training developed by public health officials and food safety experts for reopening your business. Each module contains best practices and procedures that will give your staff and guests the confidence you’re doing everything possible to ensure their safety. While some of these modules are specific to the restaurant industry, others are for all businesses.
COVID-19 has disrupted the lives of millions and is having significant impacts on businesses. North Carolina’s small business service providers are here to help you navigate this unprecedented event.
The Small Business Center Network of North Carolina is here to help you navigate challenges associated with COVID-19. Funded by your tax dollars, our services are free.
Duke Margolis Center for Health Policy COVID-19 Response
Duke-Margolis faculty and researchers from Duke University and Duke Health System, and leaders from across the health care and health policy landscape are working together to advance collective recommendations to address the COVID-19 pandemic. The Center will be releasing new working papers, holding informational webinars, and centralizing useful resources for the policy community in the coming days and weeks.
Updates from the FDA (FDA)
Interim Guidance for Businesses and Employers (CDC)
This interim guidance is based on what is currently known about the coronavirus disease 2019 (COVID-19). The Centers for Disease Control and Prevention (CDC) will update this interim guidance as needed and as additional information becomes available.
Also see the CDC's Business Pandemic Influenza Planning Checklist and Pandemic Preparedness Planning for US Businesses with Overseas Operations.
Information for Laboratories (CDC)
This page includes interim guidance and resources for laboratory professionals working with specimens from persons under investigation (PUI) for coronavirus disease 2019 (COVID-19).
Worker Training Program (NIEHS)
The NIEHS Worker Training Program (WTP) has been tracking information about the coronavirus disease 2019 (COVID-19) as it pertains to protecting workers involved in emergency response and cleanup activities performed in the United States. This page contains health and safety resources for workers who may be at risk of exposure to COVID-19.
Ultimate Guide to Supply Chain Resiliency Success (Resilinc)
This document provides supply chain risk management and resiliency strategies and practices.
Best Practices for Establishing a Cross-Functional Team (NC Chamber)
This best practice document offers guidance on establishing a cross-functional team tasked with preparation, communication and incident response.
COVID-19 Control and Prevention (OSHA)
OSHA has developed this interim guidance to help prevent worker exposure to COVID-19.
Also see OSHA's 2017 Guidance on Preparing Workplaces for an Influenza Pandemic.
Strategic Preparedness and Response for the new coronavirus (WHO)
This strategic preparedness and response plan outlines the public health measures that the international community stands ready to provide to support all countries to prepare for and respond to COVID-19.
Healthcare Planning Checklist (DHHS)
Planning for a potential emerging infectious disease pandemic, like COVID-19, is critical to protecting the health and welfare of our nation. This checklist identifies specific activities your jurisdiction can do now to prepare for, respond to, and be resilient in the face of COVID-19.
Families First Coronavirus Response Act: Employer Paid Leave Requirements (US Department of Labor)
The Families First Coronavirus Response Act (FFCRA or Act) requires certain employers to provide their employees with paid sick leave or expanded family and medical leave for specified reasons related to COVID-19. This page provides guidance about this new law.
Also see this Q&A with Hutchison PLLC regarding these new requirements.
North Carolina News
Duke Launches National Network to Bring COVID-19 Support Directly to People
The PRN is a network of organizations aligned to serve the needs of individuals and communities during the pandemic, especially those that are hardest-hit by COVID-19. PRN partners serve essential service workers and individuals who work in long term care; advocate for Hispanic communities and communities of older adults; provide medical care to vulnerable communities; and provide software products focused on employee information security and social service referrals.
Durham Medical AI Leader TeraRecon Makes Quick Shift to COVID-19 Imaging
The last few years have been good to TeraRecon, a Durham company that builds comprehensive medical imaging software using artificial intelligence. In 2017, it released a large algorithm marketplace, and a year later it launched a “results explorer,” which displays the AI-processed images in an interactive and efficient dashboard that gives physicians optimum control.
Durham-based IQVIA to Manage Clinical Trial of Hydroxychloroquine Vs. COVID-19
Durham-based IQVIA (NYSE: IQV) has been selected to manage COVID SHIELD, an Australian clinical study of hydroxychloroquine, the drug President Trump said he has been taking to prevent a COVID-19 infection.
Duke's one-hour coronavirus antibody test could be a 'game-changer'
As the world hunts for effective means for testing and screening populations for Covid-19, Duke University researchers have developed a test to detect antibodies for the virus – in less than an hour. In partnership with private industry, researchers at the Duke-NUS Medical School in Singapore have developed a new blood test that will detect the presence of neutralizing antibodies for Covid-19.
Article behind paywall.
Orion Plans AI Strategy to Design Vaccines Against COVID-19
Orion Integrated Biosciences, a Kansas-based biodefense company with a growing presence in North Carolina, plans to use artificial intelligence to design vaccines to fight COVID-19. The company says its vaccine design strategy will use powerful AI algorithms it developed from very large datasets of genomic information.
Grifols Expands Plasma Collection Centers in Search for COVID-19 Treatment
If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find a potential treatment for the disease. Grifols, one of the leading producers of plasma-based medicines, is expanding its plasma collection program in North Carolina and beyond. The goal is to develop an immunoglobulin that can treat COVID-19.
A Star Medical Researcher Looks at the Coronavirus
Dr. Tony Atala—an international leader in the field of regenerative medicine, which creates tissues that can replace failing body parts—discusses COVID-19.
What they’re trained for: Biomedical engineers at UNC-Chapel Hill and NC State respond to COVID-19 by teaming to speed the development of an emergency ventilator
The Carolina Respiratory Emergency – Ventilator (CaRE-Vent) team is advancing knowledge in the biomedical design community about how to create emergency ventilators. Biomedical engineering student Kathlyne Bautista always knew that her coursework and training would set her on a path to make a life-changing difference for people. But before the coronavirus pandemic, she didn’t realize just how soon that opportunity would arrive.
RedHill Approved for US COVID-19 Study
Fresh off a small – but successful – COVID-19 study in Israel, RedHill Biopharma has received approval to test its investigational drug, opaganib, in the United States.
UNC-CH Ranks Tops Among US Universities in Coronavirus Research
If you’ve gotten the impression that North Carolina is a hotbed of research and development to combat the COVID-19 coronavirus, you’d be right. Nowhere is that more evident than at the University of North Carolina at Chapel Hill, home to some of the top coronavirus experts in the world and the highest-ranked U.S. university for coronavirus research.
LabCorp making COVID-19 antibody tests available to individuals
LabCorp is making its recently launched COVID-19 anti-body test available to individuals. Interested individuals can visit LabCorp.com for more details.
“With the addition of this latest offering, individuals have the ability to receive the COVID-19 IgG antibody test from their doctor, in person or through a telemedicine program, and now directly using LabCorp.com,” the company says.
Grifols To Develop Plasma-Derived Treatment for COVID-19
Grifols, one of the world’s leading producers of plasma-based medicines, is collecting a blood product from recovered COVID-19 patients to develop a possible treatment for the coronavirus disease.
All hands on deck: COVID-19 engineering response team assembles from every corner at Duke
At the beginning of 2020, Dr. Alejandro Pino’s attention was focused on designing and patenting feeding tubes that can unclog themselves while also pursuing a pulmonology and critical care fellowship in the Duke University School of Medicine. Just a few months later, a novel coronavirus turned the world upside down, and feeding tubes were no longer Pino’s most pressing project.
Golden LEAF offers another $125M in COVID-19 disaster loans for small businesses
Golden LEAF, a statewide economic development group, is making another $125 million in loans available to small businesses across North Carolina following the N.C. General Assembly’s passage of a COVID-19 pandemic relief bill that was signed into law Monday by Gov. Roy Cooper.
The UNC System Contributes to Combating COVID-19
The UNC System’s response to COVID-19 offers a vivid reminder that higher education is about much more than delivering information. Collectively, our institutions serve North Carolina through instruction, research, and service. The UNC System’s contributions to the state’s efforts to combat this pandemic underscore the long-term value of supporting this mission.
This page compiles stories about how the UNC System is responding through research, service and driving economic growth.
Durham’s Chimerix Gets FDA Nod to Test Cancer Drug in COVID-19 Patients
Chimerix has gotten the green light to test an investigational cancer drug to treat COVID-19 patients. The Durham-based biopharmaceutical company announced it has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2/3 study ofdociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI).
‘A game changer’ — Drug tested in UNC labs shows positive results for COVID-19 treatment
A treatment that reduces recovery time for patients with COVID-19 showed positive results in clinical trials, UNC-Chapel Hill announced Wednesday. The medication, called remdesivir and originated in the labs at UNC-CH, has been a critical piece of the effort to fight the coronavirus pandemic. On Wednesday, the nation’s coronavirus task force shared the positive results that it accelerates recovery.
Feeling the Heat from COVID-19? Heat Biologics May Have an Answer
For those feeling the health and economic heat from COVID-19 – and that’s just about everyone – Heat Biologics says it could soon offer up a potential solution. The Morrisville-based clinical-stage biotech company specializes in disease-fighting therapies that activate patients’ immune systems. So it is working on a vaccine that tackles the COVID-19 coronavirus on two fronts.
MedPharm Expands Testing Models to Target Coronavirus
MedPharm has expanded its testing models to support pharmaceutical development programs targeting Coronavirus treatments. These models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial) and deep lung (alveolar) epithelia against members of the Coronaviridae family.
LabCorp Expands Reach of COVID-19 Antibody Test
A LabCorp blood test that helps identify individuals who’ve been exposed to the COVID-19 coronavirus is now broadly available. The Burlington-based life science company, which originally targeted the antibody blood analysis to healthcare workers, now offers it to anyone recommended for testing by a doctor or healthcare provider.
RedHill Experimental Drug Shows Promise As COVID-19 Treatment
Finally, a little encouraging news on the COVID-19 coronavirus front. RedHill Biopharma, an Israeli specialty company with U.S. commercial headquarters in Raleigh, reports that all six COVID-19 patients who recently received its investigative drug, opaganib, got better.
Duke Gets Grant to Develop ‘Fast, Simple, Low-Cost’ COVID-19 Test
Duke University biomedical engineers are hoping a rapid testing platform originally designed to detect Ebola can now be used to catch antigens to COVID-19. Now thanks to a $119,000 grant from the National Science Foundation, the team is getting to put it to the test.
Metabolon Study to Provide Better Understanding of COVID-19
Why do some patients die from the COVID-19 coronavirus, while others have symptoms so mild they may not even realize they’re sick? How can treatments for the disease work in some cases, while having no positive effect in others? These are just a couple of the questions Metabolon, a Morrisville-based precision health company, hopes to answer during a year-long COVID-19 study it is conducting with the Institute for Systems Biology (ISB).
Recovered COVID-19 Patients Can Donate Plasma at UNC, Some Grifols Plasma Centers
Americans who have recovered from COVID-19 may help save others from the disease by donating their convalescent plasma at the University of North Carolina in Chapel Hill, or at plasma donor sites operated elsewhere around the country by the global biotherapeutics company Grifols.
LabCorp Offers Home Testing Kit for COVID-19
Healthcare workers and first responders who have symptoms of COVID-19 now can use a LabCorp kit to self-test for the coronavirus at home. The Burlington-based life sciences company has received Emergency Use Authorization (EUA) from the Food and Drug Administration, which allows patients to collect nose swab specimens with LabCorp’s Pixel COVID-19 kit. It is the first coronavirus diagnostic test authorized by the FDA that has a home collection option.
Why a North Carolina facility could soon be mass producing a coronavirus treatment
Grifols (NASDAQ: GRFS), a Spanish pharmaceutical company that calls Johnston County home to its largest manufacturing site, has begun the process of identifying, screening and selecting recovered coronavirus patients to donate plasma. The collected plasma will be used to produce a therapeutic — specifically a hyperimmune globulin — that Grifols hopes will be an effective treatment for the disease.
Article behind paywall.
RedHill Pursues Two Potential COVID-19 Treatments
RedHill Biopharma is another step closer to getting one of its potential treatments for COVID-19 tested.The Israeli company, which has its U.S. headquarters and commercial operations in Raleigh, got the green light to provide its investigational drug, RHB-107 (upamostat, WX-671), for testing in non-clinical studies against the coronavirus.
NC State Students Make Shields to Protect Medical Workers from COVID-19
Healthcare workers on the coronavirus frontline continue to risk their own lives to care for the sick. However, a group of graduate student volunteers at North Carolina State University’s Mechanical and Aerospace Engineering Department are determined to protect them.
BioCryst to Test Anti-Viral Treatment for COVID-19 in Brazil
Durham-based BioCryst Pharmaceuticals will conduct a clinical trial in Brazil to see if its investigational anti-viral drug is effective in treating the COVID-19 coronavirus. The therapy, galidesivir, will be used in a two-phase study of hospitalized adults who have moderate to severe COVID-19 infections.
Open science drug discovery partnership aims to invest $125 million to prevent future pandemics
On Wednesday, the Structural Genomics Consortium, the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation announced the launch of the Rapidly Emerging Antiviral Drug Development Initiative, a global organization aimed at discovering and developing drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.
Cellex Cleared to Market Antibody Test for COVID-19
Cellex, a medical diagnostics company with U.S. headquarters and labs in Research Triangle Park, has launched a new antibody test for detecting COVID-19 infection.The company’s qSARS-COV-2 IgG/IgM Rapid Test is permitted for distribution and use under the public health emergency guidance issued by the U.S. Food and Drug Administration.
UNC researchers playing key role in development of potential COVID-19 treatment
Scientists are hopeful that a new drug, called EIDD-2801, could change the way doctors treat COVID-19. The drug shows promise in reducing lung damage, has finished testing in mice and will soon move to human clinical trials.
Advanced Animal Diagnostics Prepares COVID-19 Test for Humans
Advanced Animal Diagnostics (AAD) usually makes tests to help farmers monitor the health of their livestock. But in the age of coronavirus, the Research Triangle Park company is pivoting. The young ag tech firm is “repurposing” its QScout blood test platform, which is usually used to detect disease in cattle, to now be used for humans in the fight against COVID-19.
BioMedomics Teams with BD to Launch Rapid COVID-19 Test
Morrisville-based BioMedomics, a small diagnostics company supported by the North Carolina Biotechnology Center, has partnered with BD (Becton Dickinson & Co.) to launch its new blood test for COVID-19 that can detect the infection within 15 minutes.
Duke to Lead $50 Million Study of COVID-19 Prevention in Healthcare Workers
The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine (HCQ) as a preventive drug for the novel coronavirus.
NC Startup Awaits FDA OK for ‘Low-Cost’ COVID-19 Ventilator
As the world grapples with a shortage of ventilators for COVID-19 patients, a small North Carolina life science startup has designed a low-cost option. BioMedInnovations (BMI), headquartered outside Charlotte with a research lab in Research Triangle Park, hopes to get federal fast-track approval this week to manufacture and distribute its uniquely simple device to help people breathe.
Carolina Liquid Chemistries Introduces Tests for COVID-19, Norfentanyl
Carolina Liquid Chemistries – a Greensboro diagnostics and drug screening company – has introduced two new immunoassays to test for COVID-19 and for norfentanyl, the major metabolite of the synthetic opioid pain reliever fentanyl.
Novan explores potential COVID-19 treatment, raises $8 million
A Triangle company that's struggled to develop its lead asset has brought in $8 million through a new public offering as it unveils plans to explore potential applications of its platform in the fight against COVID-19.
Article behind paywall
Q2 Solutions, U of Texas Medical Branch Team Up to Help Find COVID-19 Vaccines
Q2 Solutions, a clinical trial laboratory services organization headquartered in Morrisville, has teamed up with the University of Texas Medical Branch to develop an assay for analyzing COVID-19 vaccine candidates.
Grifols Developing Potential Treatments for COVID-19
Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and test a potential COVID-19 therapy derived from the blood plasma of patients who have recovered from the coronavirus infection.
NC's Gilero Uses Ingenuity, 3D Printing to Expand COVID-19 Protective Equipment, Ventilators
Using 3D printers, Morrisville medical device manufacturer Gilero has begun a three-tiered response to the shortage of COVID-19 protective equipment for healthcare workers.
Duke Starts Novel Decontamination of N95 Masks to Help Relieve Shortages
Facing a critical shortage of N95 face masks that block the coronavirus, Duke Health research and clinical teams have confirmed a way to use existing vaporized hydrogen peroxide methods to decontaminate the masks so they can be reused.
Duke joins first national effort to test potential COVID-19 therapy
Adults with severe symptoms of the novel illness will have the opportunity to participate in Duke University Hospital’s test of an investigational treatment with an antiviral agent known as remdesivir. Remdesivir is an antiviral agent that was previously tested in humans with Ebola virus disease and has shown promise in animal studies against MERS and SARS, diseases that emerged from different strains of the coronavirus.
Heat Biologics, University of Miami Developing Quick Point-Of-Care COVID-19 Test
Heat Biologics, a publicly traded North Carolina biotechnology company, is adding a rapid point-of-care COVID-19 diagnostic test to its product development pipeline. The new test is in addition to the provisional patent application the Morrisville company filed March 3 to apply its immune system activating technology to prevent and/or treat COVID-19.
LabCorp Able to Perform 20,000 COVID-19 Tests Per Day
LabCorp says it’s ahead of schedule in ramping up its capacity to conduct COVID-19 tests, and is now able to perform more than 20,000 of the tests per day. The Burlington-based company says it has doubled its COVID-19 testing capacity in one week at its labs in North Carolina, Arizona and New Jersey.
NCCU Awarded Grant to Help Detect Biological Threats at the Border
North Carolina Central University has received a $330,000 grant to develop tools that help the U.S. Department of Homeland Security predict and spot risks at the border from biological threats such as COVID-19, African swine fever, and insect pests.
UNC Health deploys coronavirus test
A coronavirus test developed by Melissa Miller, director of the Clinical Molecular Microbiology Laboratory at the UNC School of Medicine, was being deployed by UNC Health on Monday, officials said. The test should help reduce some of the burden on North Carolina’s public health lab regarding testing, they said.
Medicago Vaccine Could Help Smoke Out Coronavirus
An ancient relative of tobacco, much maligned for the damage it has inflicted on public health, is key to a new vaccine to prevent the novel coronavirus. Medicago – a Canadian company with a biomanufacturing facility in Durham – has used it to produce an experimental plant-based vaccine for COVID-19, the coronavirus disease that has now reached a global pandemic level.
BioMedomics Seeks FDA OK for COVID-19 Rapid Diagnostic
Morrisville-based BioMedomics, a small diagnostics company supported by the North Carolina Biotechnology Center, has developed a new test for rapidly detecting COVID-19, the coronavirus infection that is spreading rapidly throughout the world.
Biotech firm bioMerieux, which has an HQ in Durham, working on 3 coronavirus tests
France-based bioMerieux, which has a big Triangle connection, is the latest biotech firm developing tests it says will help health officials detect the coronavirus. The company, which focuses on in vitro (test tube) diagnostics, operates its headquarters for the US, Canada and Latin America in Durham.
CDC awards North Carolina $13 million to combat coronavirus
North Carolina is set to receive more than $13 million from the Centers for Disease Control and Prevention (CDC) as part of a federal initiative to combat the coronavirus pandemic.
LabCorp is performing ‘several thousands’ of coronavirus tests per day to meet surge in demand
Burlington-based life science conglomerate LabCorp says it is now performing “several thousands” of coronavirus tests per day in the wake of an increasing number of new coronavirus infections in the United States. Meanwhile, it is rapidly adding new equipment and staff to create additional capacity for patients who should be tested across the country.
NC governor declares state of emergency as state deals with coronavirus
North Carolina Gov. Roy Cooper declared a state of emergency Tuesday as leaders continue to deal with the coronavirus outbreak. The state now has 7 people who have tested positive for COVID-19, the disease caused by the coronavirus, health officials said.
For Duke researchers – 'Every virus has an Achilles' heel'
As the novel coronavirus continues to spread across the globe, researchers are racing to create a vaccine to eradicate it, including those at Duke University who have spent decades – funded by billions of dollars– studying vaccine development for some of the world's most pressing diseases.
Article behind paywall.
What We've Learned About Coronavirus: Infectious disease experts on the spread, the science and the scenarios for the virus
Three Duke infectious disease experts talked with the media Tuesday to discuss the origins and spread of COVID-19 and the global and U.S. response. Duke plans a series of briefings on the way the novel coronavirus is affecting the world.
Keep reading for highlights from the briefing.
An air-locked lab at UNC is leading research on cures for the coronavirus
For scientists working in laboratories across the world, their names usually won’t become well known outside of the subsection of people reading academic journals. But the outbreak of COVID-19 — the disease caused by the novel coronavirus that has spread from China around the globe this year — has pushed researchers at UNC-Chapel Hill, specifically Dr. Ralph Baric, into the spotlight.
RTP firm BioMedomics says it has ‘quick and easy’ coronavirus test
BioMedomics, a medical diagnostic company based in RTP, says it has developed a novel coronavirus test that can turn around results in less than 15 minutes, potentially offering a fix to the current testing backlog.
LabCorp Launches New Test for Coronavirus
Burlington-based life science conglomerate LabCorp is the latest company to provide a test for COVID-19. This coronavirus has gained a foothold in more than 84 countries so far as it continues its unrelenting march across the globe.
NC Researchers, Companies Help Lead Coronavirus Battle
The rapid global march of the coronavirus that began in Wuhan, China several months ago could be slowed by researchers and biotech firms 7,770 miles away – in the Research Triangle of North Carolina.
Morrisville-based Heat Biologics joins global effort to discover coronavirus vaccine
The Morrisville-based biotechnology company announced today that it has formally launched a program within its wholly-owned subsidiary, Zolovax, Inc., to develop a vaccine using its immune activating gp96 vaccine platform for treating or preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19.